For research use only. Not for therapeutic Use.
Dazopride fumarate（Cat No.:I025564）is a compound being investigated for its potential therapeutic effects in gastrointestinal disorders. It is a serotonin 5-HT3 receptor antagonist and 5-HT4 receptor agonist, which means it may help modulate gut motility and reduce symptoms like nausea, vomiting, and abdominal discomfort. By targeting these serotonin receptors, dazopride fumarate may improve gastrointestinal transit and reduce excessive gut contractions. It has been explored for conditions such as irritable bowel syndrome (IBS) and functional dyspepsia. Though promising in preclinical and early clinical studies, further research is needed to confirm its efficacy and safety in these conditions.
| Catalog Number | I025564 |
| CAS Number | 81957-25-7 |
| Synonyms | AHR-5531C, Dazopride fumarate |
| Molecular Formula | C19H27ClN4O6 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 4-amino-5-chloro-N-(1,2-diethylpyrazolidin-4-yl)-2-methoxybenzamide;(E)-but-2-enedioic acid |
| InChI | InChI=1S/C15H23ClN4O2.C4H4O4/c1-4-19-8-10(9-20(19)5-2)18-15(21)11-6-12(16)13(17)7-14(11)22-3;5-3(6)1-2-4(7)8/h6-7,10H,4-5,8-9,17H2,1-3H3,(H,18,21);1-2H,(H,5,6)(H,7,8)/b;2-1+ |
| InChIKey | IGGKTAIAQUIFKQ-WLHGVMLRSA-N |
| SMILES | CCN1CC(CN1CC)NC(=O)C2=CC(=C(C=C2OC)N)Cl.C(=C/C(=O)O)\C(=O)O |
| Reference | 1: Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB. Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy. Cancer Chemother Pharmacol. 1993;31(6):442-4. PubMed PMID: 8453682. |
